Cytokinetics CYTK Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's total current assets?
- Cytokinetics (CYTK) reported total current assets of $839.47M in Q1 2026.
- How has Cytokinetics's total current assets changed year-over-year?
- Cytokinetics's total current assets decreased by 12.2% year-over-year, from $956.05M to $839.47M.
- What is the long-term trend for Cytokinetics's total current assets?
- Over 5 years (2020 to 2025), Cytokinetics's total current assets has grown at a 14.1% compound annual growth rate (CAGR), from $474.22M to $916.98M.
- What does total current assets mean?
- The sum of all assets that the company expects to turn into cash within one year.
- How do you interpret total current assets?
- A higher value indicates stronger short-term liquidity and a greater capacity to fund near-term research and development.
- How does total current assets compare across companies?
- Essential for assessing the 'runway' of biotech firms; peers with higher ratios are generally better positioned to weather clinical trial delays.